

***IN THE UNITED STATES PATENT AND TRADEMARK OFFICE***

Applicant: David CHAPLIN, et al.  
Title: CONTROL OF ACUTE HYPERTENSION AND  
CARDIOTOXICITY IN PATIENTS TREATED WITH VASCULAR  
TARGETING AGENTS  
Appl. No.: 10/602325  
Filing Date: 23-Jun-2003  
Examiner: Brian Yong S. KWON  
Art Unit: 1614  
Confirmation 1949  
Number:

**REVOCATION AND NEW POWER OF ATTORNEY BY ASSIGNEE**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

OXiGENE, Inc. is the assignee of the entire right, title and interest in United States Patent Application Serial Number 10/602325 by virtue of an assignment from the inventors recorded in the United States Patent and Trademark Office at Reel/Frame 014732/0519.

OXiGENE, Inc., through its duly-delegated representative, hereby revokes all prior Powers of Attorney submitted in this application, and hereby appoints the registered patent attorneys and patent agents associated with Customer Number:

**75605**

as their principal attorneys to have full power to prosecute this application and any continuations, divisions, reissues and reexaminations thereof, to receive the patent, to transact all business in the United States Patent and Trademark Office connected

therewith, and to have full power of substitution, association, and revocation, including the power to revoke the power of attorney of any associate attorney.

Please direct all future correspondence concerning this application to:

Karen E. Flick  
OXiGENE, Inc.  
Customer Number: 75605

Telephone: (650) 284-5575  
Facsimile: (650) 284-5596

Executed this 30 th day of April, 2008.

OXiGENE, Inc.

By:



James B. Murphy  
(Signature)

James B. Murphy  
Vice President and Chief Financial Officer